Cushing’s syndrome Market Size to Grow Exponentially During 2017 – 2025

Cushing’s syndrome is the collection of symptoms caused due to the high level of hormones called cortisol. Also known as hypercortisolism, the syndrome is often caused due to side effects of corticosteroid treatment. Corticosteroids are often used for treatment of inflammation and autoimmune conditions. Cushing’s syndrome can be of two types, iatrogenic Cushing’s syndrome and endogenous Cushing’s syndrome. Common symptoms of the syndrome include weight gain, fat tissue deposits around midsection and back, purple stretch marks, thinning skin which can be easily bruised, acne etc.

Request Report Brochure @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=30617

The global Cushing’s syndrome market is expect to expand at a robust CAGR during the forecast period. Cushing’s syndrome is a rare disease and according to UCLA Health, the syndrome affects 10 to 15 people per million each year. Increasing prevalence of the disease is one of the important factors projected to drive the global Cushing’s syndrome market through 2025. Surge in prevalence of chronic diseases leading to increase in usage of corticosteroids is another factor likely to drive the market during the forecast period. The launch of novel drugs such as steroidogenesis inhibitors for treatment of Cushing’s syndrome is the key factor projected to propel the growth of the global Cushing’s syndrome market during the forecast period. Furthermore, unhealthy lifestyle, increase in geriatric population, and steroid abuse are factors attributed to the growth of the market. Difficulties in diagnosis, sparsely populated pipeline products, strict regulations etc are factors restraining the growth of the global Cushing’s syndrome market.

The global Cushing’s syndrome market can be segmented into type, treatment, end users, and geographical expansion. On the basis of disease type, the market can be divided into iatrogenic Cushing’s syndrome and endogenous Cushing’s syndrome. On the basis of treatment, the market is divided into surgery, radiation therapy, drugs and others. The drugs segment is further divided into drug types such as Ketoconazole, Etomidate, Pasireotide, Aminoglutethimide and others. The drug segment is expected to hold a significant share during the forecast period due to factors such as effectiveness of drugs, their noninvasive nature, and fewer side effects than radiation therapies. The global Cushing’s syndrome market, on the basis of end users is segmented into hospitals, clinics, home care settings and others.

Enquiry for discount on this report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=30617

Geographically the Cushing’s syndrome market is divided into North America, Latin America, Europe, Asia Pacific, and Middle East & Africa. North America dominates the market with the largest share in the global Cushing’s syndrome market. Increase in prevalence of obesity in young adults and children in the region leading to Cushing’s syndrome is one of the major factors driving the growth of the market in the region. Furthermore, advanced technology, rise in awareness among people about diagnosis of the disease, high healthcare expenditure etc. are some of the factors attributed to the growth of the North America Cushing’s syndrome market. Europe is also anticipated to hold a significant share of the global market, after North America. The Asia Pacific market is anticipated to register a faster growth rate during the forecast period. Asia Pacific is the most lucrative market due to growing geriatric population, adoption of healthcare solutions for better standard of life, rise in awareness about healthcare, prevalence of lifestyle related diseases etc.

To maintain a significant position in the market, key players in the global Cushing’s syndrome market are operating strategies such as mergers and acquisitions, cost effective and efficient drugs, collaborative partnerships etc. Some of the prominent players operating in the Cushing’s syndrome market are Novartis Pharmaceuticals Corporation, Corcept Therapeutics, HRA Pharma and others.

Request for the TOC of the Report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=T&rep_id=30617

About Us

Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.

Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through adhoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.

TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.

US Office Contact

90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: https://www.transparencymarketresearch.com

Leave a Reply

Your email address will not be published. Required fields are marked *